$1.17 Billion is the total value of Camber Capital Management LP's 44 reported holdings in Q3 2015. The portfolio turnover from Q2 2015 to Q3 2015 was 44.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| TEVA | Buy | TEVA PHARMACEUTICAL INDS LTDadr | $112,920,000 | +9.2% | 2,000,000 | +14.3% | 9.67% | +37.4% |
| MDCO | MEDICINES CO | $94,900,000 | +32.7% | 2,500,000 | 0.0% | 8.13% | +66.9% | |
| AZN | Buy | ASTRAZENECA PLCsponsored adr | $79,550,000 | -0.1% | 2,500,000 | +100.0% | 6.82% | +25.7% |
| CYBX | CYBERONICS INC | $60,780,000 | +2.2% | 1,000,000 | 0.0% | 5.21% | +28.6% | |
| MYL | New | MYLAN NV | $60,390,000 | – | 1,500,000 | +100.0% | 5.17% | – |
| NUVA | NUVASIVE INC | $53,042,000 | +1.8% | 1,100,000 | 0.0% | 4.54% | +28.0% | |
| GHDX | Buy | GENOMIC HEALTH INC | $51,842,000 | -11.2% | 2,450,000 | +16.7% | 4.44% | +11.8% |
| OFIX | ORTHOFIX INTL N V | $50,625,000 | +1.9% | 1,500,000 | 0.0% | 4.34% | +28.2% | |
| ESRX | Sell | EXPRESS SCRIPTS HLDG CO | $48,576,000 | -27.2% | 600,000 | -20.0% | 4.16% | -8.4% |
| SEM | Buy | SELECT MED HLDGS CORP | $46,937,000 | -17.2% | 4,350,000 | +24.3% | 4.02% | +4.2% |
| LH | LABORATORY CORP AMER HLDGS | $43,388,000 | -10.5% | 400,000 | 0.0% | 3.72% | +12.6% | |
| MJN | New | MEAD JOHNSON NUTRITION CO | $42,240,000 | – | 600,000 | +100.0% | 3.62% | – |
| UAM | Buy | UNIVERSAL AMERN CORP NEW | $40,185,000 | -24.1% | 5,875,000 | +12.2% | 3.44% | -4.6% |
| MASI | Sell | MASIMO CORP | $38,560,000 | -47.6% | 1,000,000 | -47.4% | 3.30% | -34.1% |
| ARIA | Sell | ARIAD PHARMACEUTICALS INC | $32,313,000 | -32.0% | 5,533,118 | -3.8% | 2.77% | -14.5% |
| NKTR | Buy | NEKTAR THERAPEUTICS | $24,660,000 | +31.4% | 2,250,000 | +50.0% | 2.11% | +65.3% |
| SQNM | Buy | SEQUENOM INC | $20,563,000 | -24.8% | 11,750,000 | +30.6% | 1.76% | -5.4% |
| CCRN | CROSS CTRY HEALTHCARE INC | $20,330,000 | +7.3% | 1,493,765 | 0.0% | 1.74% | +35.0% | |
| ALNY | New | ALYNYLAM PHARMACEUTICALS INC | $20,090,000 | – | 250,000 | +100.0% | 1.72% | – |
| HMSY | New | HMS HLDGS CORP | $19,118,000 | – | 2,179,900 | +100.0% | 1.64% | – |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $18,623,000 | -46.5% | 9,750,000 | +30.0% | 1.60% | -32.7% |
| THC | New | TENET HEALTHCARE CORP | $18,460,000 | – | 500,000 | +100.0% | 1.58% | – |
| KND | KINDRED HEALTHCARE INC | $17,325,000 | -22.4% | 1,100,000 | 0.0% | 1.48% | -2.4% | |
| INNOCOLL AGsponsored adr | $14,089,000 | -13.8% | 1,111,111 | 0.0% | 1.21% | +8.4% | ||
| DGX | Sell | QUEST DIAGNOSTICS INC | $13,431,000 | -25.9% | 218,500 | -12.6% | 1.15% | -6.7% |
| AMRN | Sell | AMARIN CORP PLCspons adr new | $12,545,000 | -49.0% | 6,500,000 | -35.0% | 1.08% | -35.8% |
| ABT | New | ABBOTT LABS | $12,066,000 | – | 300,000 | +100.0% | 1.03% | – |
| DRRX | Buy | DURECT CORP | $11,700,000 | -2.1% | 6,000,000 | +20.0% | 1.00% | +23.1% |
| BIOS | Buy | BIOSCRIP INC | $11,220,000 | -33.5% | 6,000,000 | +29.0% | 0.96% | -16.4% |
| OSUR | Buy | ORASURE TECHNOLOGIES INC | $8,880,000 | +26.8% | 2,000,000 | +53.9% | 0.76% | +59.5% |
| PLX | PROTALIX BIOTHERAPEUTICS INC | $8,584,000 | -39.5% | 7,274,577 | 0.0% | 0.74% | -23.9% | |
| EPRSQ | EPIRUS BIOPHARMACEUTICALS IN | $8,166,000 | -22.6% | 1,847,500 | 0.0% | 0.70% | -2.5% | |
| CATB | Buy | CATABASIS PHARMACEUTICALS IN | $8,090,000 | -28.6% | 1,000,000 | +7.8% | 0.69% | -10.1% |
| NVTA | Buy | INVITAE CORP | $6,455,000 | -13.2% | 894,014 | +78.8% | 0.55% | +9.1% |
| PODD | New | INSULET CORP | $6,348,000 | – | 245,000 | +100.0% | 0.54% | – |
| PROTALIX BIOTHERAPEUTICS INCnote 4.500% 9/1 | $6,182,000 | -11.2% | 9,000,000 | 0.0% | 0.53% | +11.8% | ||
| GNMK | Sell | GENMARK DIAGNOSTICS INC | $5,699,000 | -38.2% | 724,097 | -28.9% | 0.49% | -22.3% |
| BIOL | BIOLASE INC | $4,799,000 | -48.3% | 5,332,394 | 0.0% | 0.41% | -35.0% | |
| VCYT | Sell | VERACYTE INC | $4,269,000 | -68.8% | 910,334 | -25.8% | 0.37% | -60.7% |
| ANGO | Sell | ANGIODYNAMICS INC | $3,405,000 | -71.8% | 258,183 | -64.9% | 0.29% | -64.4% |
| UNIS | New | UNILIFE CORP NEW | $2,695,000 | – | 2,750,000 | +100.0% | 0.23% | – |
| CRDC | CARDICA INC | $2,412,000 | -42.3% | 8,374,846 | 0.0% | 0.21% | -27.4% | |
| CBIO | New | CATALYST BIOSCIENCES INC | $899,000 | – | 192,935 | +100.0% | 0.08% | – |
| AZN | New | BIOLASE INCcall | $3,000 | – | 1,841,173 | +100.0% | 0.00% | – |
| BIOL | Exit | BIOLASE INCcall | $0 | – | -1,841,173 | -100.0% | -0.01% | – |
| TRGT | Exit | TARGACEPT INC | $0 | – | -1,560,000 | -100.0% | -0.30% | – |
| KERX | Exit | KERYX BIOPHARMACEUTICALS INC | $0 | – | -500,000 | -100.0% | -0.34% | – |
| PRGO | Exit | PERRIGO CO PLC | $0 | – | -122,748 | -100.0% | -1.54% | – |
| XRAY | Exit | DENTSPLY INTL INC NEW | $0 | – | -500,000 | -100.0% | -1.76% | – |
| CI | Exit | CIGNA CORPORATION | $0 | – | -300,000 | -100.0% | -3.31% | – |
| JNJ | Exit | JOHNSON & JOHNSONcall | $0 | – | -500,000 | -100.0% | -3.32% | – |
| XLV | Exit | SELECT SECTOR SPDR TRput | $0 | – | -1,000,000 | -100.0% | -5.06% | – |
| SPY | Exit | SPDR S&P 500 ETF TRput | $0 | – | -500,000 | -100.0% | -7.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2015-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICALS INDS LTD | 34 | Q3 2023 | 9.7% |
| BROOKDALE SR LIVING INC | 32 | Q3 2023 | 5.0% |
| PERRIGO CO PLC | 29 | Q3 2023 | 7.1% |
| TENET HEALTHCARE CORP | 28 | Q3 2023 | 8.5% |
| NEKTAR THERAPEUTICS | 28 | Q1 2022 | 9.8% |
| UNIVERSAL HLTH SVCS INC | 25 | Q3 2023 | 9.9% |
| MYRIAD GENETICS INC | 24 | Q3 2023 | 5.0% |
| SAREPTA THERAPEUTICS INC | 23 | Q3 2023 | 6.0% |
| MYLAN NV | 21 | Q3 2020 | 10.1% |
| AMAG PHARMACEUTICALS INC | 21 | Q3 2020 | 4.0% |
View Camber Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC | February 02, 2023 | ? | ? |
| Solid Biosciences Inc. | December 12, 2022 | ? | ? |
| AVROBIO, Inc. | February 14, 2022 | ? | ? |
| COLLEGIUM PHARMACEUTICAL, INC | February 14, 2022 | ? | ? |
| AMAG PHARMACEUTICALS, INC. | February 16, 2021 | ? | ? |
| Atara Biotherapeutics, Inc. | February 16, 2021 | ? | ? |
| Change Healthcare Inc. | February 16, 2021 | ? | ? |
| GLYCOMIMETICS INC | February 16, 2021 | ? | ? |
| Clovis Oncology, Inc. | February 14, 2020 | ? | ? |
| Cyclerion Therapeutics, Inc. | February 14, 2020 | ? | ? |
View Camber Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-30 |
| 13F-HR | 2023-08-14 |
View Camber Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.